GLP-1 Medications and Cancer Survivorship

Weight Management, Metabolic Recovery and an Emerging Role After Cancer Treatment

 

Cancer treatment increasingly succeeds in extending life, but survivorship can introduce an entirely different set of health challenges. For many people, completing chemotherapy, radiation, surgery or other treatment does not mean returning immediately to their previous state of health. Weight gain, loss of muscle, insulin resistance, cardiovascular risk, fatigue, hormonal changes and reduced physical conditioning may persist long after treatment has ended.

 

Against this background, glucagon-like peptide-1 receptor agonists—commonly referred to as GLP-1 medications—have attracted considerable interest among patients, cancer survivors and healthcare professionals.

 

Medications such as semaglutide and liraglutide act on the GLP-1 receptor, while tirzepatide acts on both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors. These medications were developed principally for diabetes and obesity management. They are not cancer treatments, nor has it been established that they prevent cancer recurrence or metastasis.

 

Their potential importance in cancer survivorship arises from a different question: Could GLP-1–based therapy help appropriately selected cancer survivors address obesity, insulin resistance and other metabolic consequences that may develop during and after cancer treatment?

 

Current evidence suggests that this is an important area for clinical consideration and further research.

 

Why Weight Gain Happens During and After Cancer Treatment

Weight gain following cancer treatment should not automatically be viewed as a cosmetic problem or simply a consequence of overeating. In many survivors, the underlying causes are physiological, behavioral and treatment-related.

 

Corticosteroids. Drugs such as dexamethasone are frequently administered to prevent nausea, reduce inflammation or manage treatment reactions. Corticosteroids can increase appetite, influence glucose metabolism, promote fluid retention and alter fat distribution.

 

Hormonal therapy. Treatments that reduce estrogen or testosterone may affect metabolism and body composition. Endocrine therapy used for breast cancer and androgen-deprivation therapy used for prostate cancer can contribute to increased body fat, reduced muscle mass and changes in insulin sensitivity.

 

Chemotherapy and other systemic therapies. Fatigue, reduced activity and prolonged interruption of normal exercise can decrease energy expenditure. Treatment may also change appetite and eating patterns. Some patients find that higher-calorie or carbohydrate-rich foods are among the few foods they tolerate during periods of nausea.

Treatment-related deconditioning. Surgery, radiation, hospitalization and prolonged inactivity can produce losses in strength and cardiorespiratory fitness. A person may consequently burn fewer calories while simultaneously experiencing metabolic changes.

Menopause and hormonal disruption. Treatment-induced menopause or suppression of sex hormones can further alter fat distribution, muscle mass and metabolic health. The resulting problem may therefore extend considerably beyond weight itself.

A survivor may emerge from treatment with greater visceral adiposity, less skeletal muscle, higher glucose, worsening lipid levels, hypertension and decreased exercise capacity. For some individuals, cancer survivorship becomes accompanied by a new cardiometabolic health challenge.

 

Why Metabolic Health Matters in Cancer Survivorship

Obesity has been associated with the development of multiple malignancies, and higher adiposity has also been associated with poorer outcomes in survivors of certain cancers.

 

This does not mean that losing weight has been proven to prevent cancer recurrence. That distinction is critical.

Rather, obesity can contribute to several biological conditions relevant to long-term health, including insulin resistance, hyperinsulinemia, chronic low-grade inflammation, altered sex-hormone metabolism, hypertension, dyslipidemia and cardiovascular disease. For cancer survivors, these conditions matter independently of their potential relationship to cancer.

Cardiovascular disease, diabetes and metabolic dysfunction can become significant competing health risks as survival improves. Consequently, survivorship medicine increasingly has reason to look beyond surveillance for recurrent disease and consider the patient's overall metabolic health. This is where GLP-1–based therapies become particularly interesting.

 

What GLP-1 Medications Actually Do

GLP-1–based therapies affect several physiological systems involved in appetite, glucose regulation and energy balance. Depending upon the medication, they can improve glycemic control, decrease appetite, slow gastric emptying and produce substantial reductions in body weight.

 

Large randomized obesity trials involving semaglutide and tirzepatide have demonstrated clinically meaningful weight reduction in appropriately selected populations. But for cancer survivors, the potential objective should extend beyond achieving a lower number on a scale.

 

For an appropriate patient, successful obesity treatment may contribute to improvements in:

• excess body weight and visceral adiposity;
• type 2 diabetes and prediabetes;
• insulin resistance and glucose regulation;
• hypertension;
• dyslipidemia;
• cardiovascular risk;
• metabolic fatty liver disease;
• obstructive sleep apnea;
• mobility and physical activity;
• overall metabolic health.

 

This suggests a more useful clinical concept than simply “weight-loss medication.”

For some survivors, GLP-1 therapy could potentially become one component of metabolic rehabilitation after cancer treatment.

 

The Most Important Issue: Patient Selection

There is no single answer to the question of whether GLP-1 therapy is appropriate for a cancer survivor.

Cancer survivors represent an extremely diverse clinical population. At one end of the spectrum may be a survivor who has completed active treatment and now has obesity, increasing visceral adiposity, insulin resistance, prediabetes or type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, sleep apnea or impaired mobility.

 

Hormonal treatment, corticosteroid exposure and prolonged inactivity may have contributed to these changes.

For this metabolically unhealthy survivor, medically supervised GLP-1 therapy may be a reasonable treatment consideration when otherwise clinically appropriate.

 

At the opposite end of the spectrum is a patient experiencing unintended weight loss, cancer-associated cachexia, substantial sarcopenia, nutritional compromise, poor appetite or persistent gastrointestinal symptoms from treatment. For this individual, further appetite suppression or weight reduction could be undesirable and potentially harmful.

 

The appropriate question is therefore not: “Are GLP-1 medications good for cancer survivors?”

It is: “Which cancer survivors have metabolic disease for which GLP-1 therapy may be appropriate, and which survivors have clinical circumstances that make weight-loss pharmacotherapy inappropriate?”

 

That distinction is fundamental.

 

Lean Mass Loss Requires Important Context

Another concern surrounding GLP-1 treatment involves lean body mass. This issue should be discussed carefully because some loss of lean mass commonly accompanies weight loss regardless of how the weight is lost. A reduction in measured lean mass during GLP-1 therapy should therefore not automatically be interpreted as pathologic muscle wasting or as a unique toxic effect of GLP-1 medications.

 

Cancer survivors, however, require particular attention to muscle preservation. Some patients enter survivorship having already experienced inactivity, nutritional disruption, hormonal changes, deconditioning or sarcopenia. In these individuals, rapid or poorly managed weight reduction could compound an existing problem.

 

The goal should therefore be preferential reduction of excess adiposity while preserving muscle mass, strength, function and adequate nutrition. That means GLP-1 treatment should ideally be accompanied by a comprehensive strategy incorporating:

Adequate protein intake. Nutritional intake should support muscle preservation while creating an appropriate energy deficit.

Resistance training. Progressive strength training can provide an important stimulus for maintaining or rebuilding skeletal muscle.

Appropriate dosing and rate of weight loss. Maximum medication dosing and maximum speed of weight reduction should not automatically be considered the therapeutic objective.

Body-composition monitoring. In selected survivors, assessment should extend beyond body weight and BMI to include waist circumference, body composition, strength and functional performance.

 

The clinically meaningful question becomes: What did the patient lose—and what did the patient preserve?

A survivor who reduces excess adipose tissue while preserving muscle and becoming stronger may achieve a very different outcome from someone who loses the same number of pounds while becoming weaker and nutritionally compromised.

 

What Are We Seeing About Cancer Incidence?

An especially interesting area of research concerns associations between GLP-1 use and cancer incidence.

Large observational studies involving patients with obesity and/or diabetes have reported associations between GLP-1 receptor agonist use and lower incidence of certain obesity-associated cancers. These findings are scientifically important, but they must be interpreted cautiously.

 

Observational research cannot establish that the medication itself prevented cancer. People prescribed GLP-1 medications may differ from comparison groups in numerous ways, including weight trajectory, glucose control, cardiovascular management, healthcare utilization and other medications.

 

Furthermore, any apparent reduction in cancer incidence could theoretically reflect weight reduction, improved insulin sensitivity, changes in inflammation, other metabolic improvements or combinations of these factors.

Consequently, the evidence should currently be described as an interesting epidemiological signal requiring prospective investigation—not proof of cancer prevention.

 

What About Cancer Recurrence and Progression?

Emerging retrospective and observational studies have also generated interest in possible relationships between GLP-1 therapy and cancer progression. These findings deserve research attention, but the same caution applies.

At present, GLP-1 medications have not been demonstrated in prospective randomized oncology trials to prevent recurrence, inhibit metastasis or treat established cancer.

 

Any association between GLP-1 exposure and improved cancer outcomes should therefore be considered hypothesis-generating. There are biologically plausible reasons researchers are interested in the subject. Obesity, insulin resistance, hyperinsulinemia, altered sex-hormone metabolism and chronic metabolic inflammation have relationships with several cancers.

 

Improving that metabolic environment could conceivably influence cancer biology. But plausible biology is not proof of therapeutic effect. The responsible scientific conclusion is that the early observations are sufficiently interesting to justify dedicated clinical trials.

 

Breast Cancer Survivorship Is Particularly Relevant

Breast cancer represents one of the most important areas for future investigation.

Many patients with hormone receptor-positive breast cancer receive endocrine therapy for years. Changes in body composition, menopausal status, physical activity and metabolic health may occur during this extended treatment period.

 

Early retrospective reports suggest that GLP-1–based medications can produce weight reduction in breast cancer survivors, including individuals receiving endocrine therapy. However, available studies remain limited in size, duration and ability to assess long-term cancer outcomes.

 

The immediate clinical rationale for GLP-1 therapy in an appropriate breast cancer survivor therefore remains treatment of obesity and metabolic disease—not prevention of breast cancer recurrence.

Similar principles apply to survivors of prostate, colorectal and other cancers in whom treatment, hormonal changes or inactivity may contribute to metabolic deterioration.

 

The Other Side of the Equation: When Weight Loss May Be Harmful

Cancer medicine presents circumstances rarely encountered in conventional commercial discussions of weight-loss medications. For some cancer patients, maintaining weight is the therapeutic priority.

 

Cancer cachexia, unintended weight loss, severe loss of muscle, malnutrition and treatment-related appetite suppression can threaten treatment tolerance and quality of life. GLP-1 medications can produce gastrointestinal adverse effects including nausea, vomiting, diarrhea, constipation and abdominal symptoms. Because many anticancer treatments can produce similar symptoms, overlapping toxicities deserve particular consideration during active treatment.

 

A patient struggling to maintain adequate caloric and protein intake may be an entirely different candidate from an obese, metabolically unhealthy survivor several years after successful treatment.

 

Timing therefore matters. So do cancer type, treatment status, nutritional condition, body composition and the reason the medication is being considered.

 

Other Safety Considerations

GLP-1–based therapies have recognized adverse effects and precautions that remain relevant to cancer survivors.

Gastrointestinal symptoms are among the most common. Gallbladder disease, pancreatitis, dehydration-related kidney problems and hypoglycemia in patients receiving certain glucose-lowering medications also require consideration.

 

Delayed gastric emptying deserves particular attention because cancer survivors may take multiple oral medications. Medication regimens should therefore be reviewed by the treating clinicians when GLP-1 therapy is initiated. Delayed gastric emptying may also be relevant for procedures requiring anesthesia or deep sedation.

 

Another frequently discussed issue involves thyroid cancer. Several GLP-1 medications carry boxed warnings concerning thyroid C-cell tumors based largely upon findings in rodents. Whether these medications cause medullary thyroid carcinoma in humans has not been established. Nevertheless, certain GLP-1 medications are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. These considerations reinforce the importance of individualized medical assessment rather than unsupervised use.

 

 

Beyond BMI: A Better Survivorship Model

The growing interest in GLP-1 therapy creates an opportunity to rethink weight management in cancer survivorship. The traditional model asks: How much does the patient weigh?

A more sophisticated survivorship model asks: What is happening metabolically and functionally to this patient?

 

Evaluation might include:

• weight and BMI;
• waist circumference;
• visceral adiposity and body composition when appropriate;
• skeletal muscle preservation;
• strength and functional capacity;
• glucose and HbA1c;
• insulin resistance when clinically relevant;
• lipid profile;
• blood pressure;
• cardiovascular risk;
• liver health;
• dietary intake and protein adequacy;
• physical activity;
• sleep;
• cancer treatment history;
• current medications;
• nutritional status.

 

GLP-1 therapy could then become one component of a broader intervention that includes exercise oncology, resistance training, nutritional support, cardiovascular prevention and metabolic medicine.

 

The Emerging Role: Metabolic Rehabilitation After Cancer

Perhaps the most useful way to understand GLP-1 therapy in oncology is not as a cancer intervention but as a potential component of post-cancer metabolic rehabilitation. Modern oncology has become increasingly effective at treating malignancy. Survivorship medicine must now address what happens to the rest of the person.

A patient may survive cancer yet emerge with obesity, diabetes, cardiovascular risk, physical deconditioning and altered body composition. Those conditions deserve treatment.

 

For an appropriately selected metabolically unhealthy cancer survivor, GLP-1–based therapy may offer an important new therapeutic option when integrated with nutrition, resistance exercise, muscle preservation and appropriate medical monitoring.

 

For another survivor—particularly someone experiencing cachexia, sarcopenia, nutritional compromise or significant treatment-related gastrointestinal symptoms—the same medication may be inappropriate.

That is why the future discussion should move beyond asking whether GLP-1 medications are simply “good” or “bad” for people with cancer.

 

The more clinically meaningful question is: Who is the right patient, at the right point in survivorship, for the right metabolic intervention?

 

The emerging cancer-incidence and progression research is fascinating and deserves rigorous investigation. But it should not overshadow what can already be addressed with greater confidence: obesity, diabetes and cardiometabolic disease are consequential health problems for many cancer survivors.

 

The goal should therefore not be weight loss at any cost. The goal is metabolic recovery—reducing excess adiposity where appropriate while protecting nutrition, muscle, strength, function and long-term health.

For selected cancer survivors, that may prove to be one of the most valuable applications of GLP-1–based medicine.

 

BEYOND TREATMENT: CAN LIFESTYLE CHANGE CANCER BIOLOGY?

Dr. Neil Iyengar Brings the Science of Precision Lifestyle Medicine to the October 2026 Male Breast Cancer Medical Summit

What if exercise could be prescribed with the same attention to dose that oncologists bring to medication? What if diet could influence biological pathways involved in tumor growth? And what if the next evolution in cancer care involved not choosing between medical treatment and lifestyle intervention—but scientifically determining how the two can work together?

These are among the provocative questions Dr. Neil Iyengar will bring to the October 2026 Male Breast Cancer Medical Summit.

Iyengar, a medical oncologist and physician-scientist who serves as Section Chief of Breast Medical Oncology and Director of Cancer Survivorship Services at Winship Cancer Institute of Emory University, is studying lifestyle intervention from a distinctly oncologic perspective. His interest extends beyond helping patients simply “feel better.” His research asks whether structured diet, exercise, weight management, and body-composition interventions can actually modify cancer biology and potentially improve response to conventional therapy.

That distinction makes his upcoming Summit presentation especially compelling.

From Wellness to Cancer Biology

Exercise, nutritional support, counseling, yoga, mental-health services, and social interventions have long demonstrated value in improving quality of life during and after cancer treatment. Iyengar describes the next scientific question as considerably more ambitious: Can researchers leverage those benefits to actually change cancer biology?

Much of this investigation has emerged from research into obesity and cancer. Obesity is associated with multiple cancers and, following a breast cancer diagnosis, with poorer outcomes, including increased risk of recurrence or faster progression. Most historical breast cancer data have come from women, but Iyengar points to a growing—although still limited—body of evidence suggesting that obesity may also be an important risk factor in male breast cancer.

The biological explanation is increasingly sophisticated. Dysfunctional adipose tissue can promote inflammation, alter cytokine signaling, contribute to DNA damage and oxidative stress, affect insulin pathways, alter immune function and the gut microbiome, and provide energy that developing cancer cells may exploit. This understanding is allowing investigators to approach lifestyle intervention almost as they would drug development: identify biological pathways, design an intervention capable of modifying them, and then measure the response.

Exercise as a Precision Intervention

Perhaps the most striking part of Iyengar’s work concerns exercise.

Evidence suggests exercise may increase tumor blood flow, improve drug delivery, alter molecular signaling involved in tumor-cell growth, and potentially reduce metastatic behavior. Observational studies involving more than 17,000 patients have also associated exercise with approximately a 40 percent reduction in breast cancer-specific mortality. Iyengar carefully emphasizes that such findings do not mean exercise replaces cancer treatment. Rather, they raise the possibility that exercise may complement standard therapy in biologically meaningful ways.

The question then becomes surprisingly similar to pharmacology: What is the correct dose?

Iyengar and colleagues recently completed a multicenter Phase I structured exercise trial involving patients with hormone receptor-positive metastatic breast cancer receiving first-line therapy. Fifty-four participants were assigned exercise doses ranging from 90 to 375 minutes per week. Treadmills were delivered to participants’ homes, sessions were remotely supervised by exercise physiologists, and wearable technology monitored fitness, body composition, blood pressure, sleep, and other measures.

Nearly all tested exercise doses proved feasible except the highest—375 minutes weekly. Most intriguing, the best one-year progression-free survival rate in this early trial was observed in the 225-minute-per-week group. Iyengar stresses that this finding must now be confirmed in larger Phase II and Phase III studies. It nevertheless provides an important foundation for studying exercise not simply as general advice, but as an individualized intervention with a potentially definable therapeutic dose.

Diet, Body Composition and a Remarkable Result

Iyengar’s research also challenges the idea that the number on a scale tells the entire story.

In a recently completed Phase II trial supported by the American Cancer Society, patients with Stage I–III estrogen-receptor-positive breast cancer receiving anti-estrogen therapy were randomized to a six-month structured plant-based diet plus exercise intervention or health education. Participants underwent biological sampling, while the intervention was highly individualized: treadmills were delivered to homes, exercise was prescribed according to individual needs, and meals were designed around personalized caloric, protein and carbohydrate requirements.

The results Iyengar presented are striking.

Participants in the intensive lifestyle arm lost approximately 17 percent of total body weight, compared with approximately 5 percent in the control group. More importantly, the intervention group demonstrated a 7 percent gain in lean mass despite the substantial weight loss. For Iyengar, this highlights why lifestyle intervention remains important even as powerful medical weight-loss therapies such as GLP-1 receptor agonists become increasingly available: weight loss alone and healthier body composition are not necessarily the same outcome.

The Emerging Model: Precision Lifestyle Oncology

Iyengar ultimately envisions cancer care in which oncologists prescribe not only anticancer therapy but also individualized lifestyle plans informed by a patient’s biology, environment, genetics, cancer type, treatment and body composition.

And this may be the most important measure of his research program’s success.

The work has moved the conversation beyond generic instructions to “eat better and exercise.” His team has completed controlled clinical studies, demonstrated that sophisticated lifestyle interventions can be delivered even into patients’ homes, identified feasible exercise doses, produced substantial improvements in weight and lean body mass, and generated hypotheses now ready for larger clinical testing.

The final question—whether these interventions can reliably improve cancer-specific survival across different populations—still requires larger and longer trials. But the research trajectory is clear.

Lifestyle oncology is moving from recommendation toward measurement, from general wellness toward precision intervention, and from the margins of cancer care toward rigorous clinical investigation. At the October Summit, Dr. Neil Iyengar will show us just how far that science has already come—and where it may take cancer treatment next.

.....................................................................................................................................................................

This article and accompanying video clip contain advance excerpts from a presentation scheduled for the 2026 Male Breast Cancer Global Alliance Medical Summit, taking place October 23–24, 2026. This feature is intended solely as an overview of the speaker’s forthcoming Summit presentation and does not constitute the complete presentation. © 2026 Male Breast Cancer Global Alliance. No portion of this article, video clip, presentation overview, or related materials may be copied, reproduced, distributed, republished, or otherwise used 

 

2026 MEDICAL SUMMIT SPEAKER REVIEW: Closing the Evidence Gap in Male Breast Cancer

Dr. Jose Pablo Leone Brings the ETHAN Trial to the 2026 Male Breast Cancer Medical Summit

When Dr. Jose Pablo Leone takes the stage as part of the Male Breast Cancer Global Alliance’s October Medical Summit, he will be discussing more than a clinical trial. He will be addressing one of the persistent problems confronting men diagnosed with breast cancer: How much of what we prescribe to men has actually been studied specifically in men?

For decades, male breast cancer treatment has necessarily drawn heavily upon research conducted predominantly among women. Yet biology, hormonal environments, treatment tolerability, and therapeutic response cannot simply be assumed to be identical. Dr. Leone, a medical oncologist at Dana-Farber Cancer Institute who treats men with breast cancer, is helping move the field toward something patients and advocates have long sought: evidence generated specifically from men.

At the center of his Summit presentation will be ETHAN (TBCRC-059), a Phase II clinical trial comparing endocrine therapies for men with early-stage breast cancer. The study is attempting to answer several fundamental treatment questions that remain surprisingly unresolved.

Tamoxifen remains the standard adjuvant endocrine therapy for most men with hormone receptor-positive breast cancer. But important uncertainties remain regarding other endocrine approaches. How effective are aromatase inhibitors in men with early-stage disease? Does combining an aromatase inhibitor with gonadal suppression produce greater activity than tamoxifen? Can the addition of a CDK4/6 inhibitor increase treatment effectiveness? And if a CDK4/6 inhibitor is used, what endocrine therapy should accompany it?

These are not abstract scientific questions. The answers could influence how physicians treat men with breast cancer for years to come.

A Trial Built Specifically Around Men

ETHAN plans to enroll 60 men with Stage I, II, or III estrogen- and/or progesterone-receptor-positive, HER2-negative breast cancer—a profile Dr. Leone notes represents approximately 95 percent of male breast cancer cases. Participants are randomized among treatment strategies involving tamoxifen, anastrozole, gonadal suppression with degarelix, and, during the later treatment phase, the CDK4/6 inhibitor abemaciclib.

Importantly, the trial examines what happens biologically while the tumor is still present. After an initial three-week treatment period, participants undergo a research biopsy. Treatment continues before surgery, allowing investigators to examine how individual tumors respond to the different endocrine strategies.

Two major measurements anchor the study: reduction in Ki67, a marker associated with tumor-cell proliferation, and the Residual Cancer Burden Index, which evaluates the amount of cancer remaining at surgery following treatment.

But ETHAN extends well beyond those two measurements.

Researchers are examining estradiol and testosterone levels, treatment safety, side effects, feasibility, quality of life, and patient-reported outcomes. Tumor samples are being collected at multiple points so investigators can compare molecular changes before and after treatment. Blood analyses are also being incorporated, and the research team is working to evaluate circulating tumor DNA—an increasingly important tool for understanding and tracking cancer, but one for which considerably less is known specifically in men.

The study's molecular ambitions are particularly significant. Investigators plan to explore genomic characteristics associated with response, hereditary mutations such as BRCA alterations, tumor-cell death, gene signatures associated with treatment sensitivity, tumor heterogeneity, and circulating tumor DNA. The larger question behind these analyses is increasingly central to precision oncology: Which treatment works best, for which patient, and why?

Progress—and the Challenge Ahead

As of September 1, 2026, Dr. Leone reported that 27 men had enrolled, with another participant in screening. The trial was operating at nine sites across the United States, with additional expansion underway. That geographic growth matters. Male breast cancer is uncommon, and recruiting sufficient numbers of eligible men into a prospective clinical trial is inherently difficult. Expanding the number of participating centers brings the research closer to patients and reduces the travel burden that can otherwise make participation impractical.

Dr. Leone is equally clear that the work is not finished. The study needs 60 participants, and enrollment has progressed more slowly than originally anticipated. Because participants must enter the study before breast surgery, awareness at the moment of diagnosis is critical. Men cannot participate after the tumor has already been surgically removed.

This makes advocacy an active component of research progress. Physicians, cancer organizations, survivors, families, and advocates can help simply by making newly diagnosed men aware that trials such as ETHAN exist.

Research Success Is Also Measured by Momentum

ETHAN has not yet produced the final comparative efficacy results it was designed to generate, so its success should not be described as a therapeutic conclusion. But there is already meaningful success in what the research infrastructure has accomplished.

Dr. Leone reported that the study enrolled 10 additional patients compared with his presentation the previous year, evidence that recruitment is moving forward despite the inherent difficulty of conducting a trial in a rare patient population. The study has expanded nationally, established collaborations among major cancer centers, incorporated sophisticated molecular investigations, and created a research platform dedicated specifically to answering questions about men with breast cancer.

That may ultimately be one of the most important messages Dr. Leone brings to the October Summit: progress in male breast cancer will not come from assuming that evidence from another population is sufficient. It will come from studying men, enrolling men, measuring their responses, and building the evidence that has been missing for too long.

ETHAN represents that movement in action. Its final answers are still ahead—but the research is advancing, participation is growing, and the scientific community is getting closer to evidence that could help define a more precise and better-informed standard of care for men with breast cancer.

.....................................................................................................................................................................

This article and accompanying video clip contain advance excerpts from a presentation scheduled for the 2026 Male Breast Cancer Global Alliance Medical Summit, taking place October 23–24, 2026. This feature is intended solely as an overview of the speaker’s forthcoming Summit presentation and does not constitute the complete presentation. © 2026 Male Breast Cancer Global Alliance. No portion of this article, video clip, presentation overview, or related materials may be copied, reproduced, distributed, republished, or otherwise used without the express written permission of the MBCGA and its Board of Directors.

AD SHOWCASE- FOR PARTNERS ONLY

THIS SHOWCASE IS FOR INTERNAL DISCUSSION ONLY:  DO NOT USE WITHOUT PERMISSION FROM OUR EDITORIAL TEAM